Ipsen S.A. ADR (IPSEY) 14.0850 $IPSEY Ipsen Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Ipsen S.A. ADR (IPSEY) 14.0850 $IPSEY

Ipsen Announces Data Presentations for Somatuline(R) Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Business Wire - Thu May 14, 8:17AM CDT
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY), today announced that abstracts of data regarding Somatuline(R) Depot (lanreotide) Injection 120 mg (referred to as Somatuline(R)) will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) being held in Chicago, Illinois, May 29 - June 2, 2015. The data include a poster discussion of a new subgroup analysis of the Phase III CLARINET(R) study in patients with midgut neuroendocrine tumors (NETs).

Ipsen reports strong sales growth in Q1 2015 and raises guidance for the year
Business Wire - Wed Apr 29, 12:00AM CDT
--Specialty care sales up 14.6%(1)

Active Bio and Ipsen call it quits in prostate cancer
Seeking Alpha - at Seeking Alpha - Thu Apr 16, 7:42AM CDT


Active Biotech and Ipsen Announce Their Decision to Discontinue the Development of tasquinimod in Prostate Cancer
Business Wire - Thu Apr 16, 12:00AM CDT
Regulatory News:

Ipsen Biopharmaceuticals expands to Canada
CNW Group - Wed Apr 15, 7:45AM CDT
International pharmaceutical company opens new headquarters in Ontario

Ipsen and Hannover Medical School Start Joint Research in Recombinant Botulinum Neurotoxins for Targeted Secretion Inhibitors
Business Wire - Wed Apr 08, 1:00AM CDT
Regulatory News:

Ipsen Expands Ties to Harvard University with Signing of a New Research Alliance Agreement
Business Wire - Wed Apr 01, 11:00AM CDT
Regulatory News:

Ipsen inaugurates new Cambridge, MA R&D center, at the heart of the most important biomedical research & innovation hub in the USA, to expand U.S. presence
Business Wire - Wed Apr 01, 6:00AM CDT
Regulatory News:

Ipsen's 2014 Results and 2015 Financial Objectives
Business Wire - Tue Mar 03, 12:00AM CST
--Core diluted EPS of EUR2.22, up 20.3%

Ipsen Announces Third Resupply of Increlex(R) (mecasermin [rDNA origin] Injection) in the U.S. in 2015
Business Wire - Mon Mar 02, 11:00AM CST
--Ipsen continues to work with the FDA to release future batches of Increlex(R)

Dominique Laymand is Appointed as Ipsen's Senior Vice President, Chief Ethics and Compliance Officer
Business Wire - Mon Mar 02, 3:00AM CST
Regulatory News:

DBV Technologies Welcomes Dr. J-P Moreau to its Scientific Advisory Board
GlobeNewswire - Fri Feb 13, 12:46AM CST
DBV Technologies, (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage specialty biopharmaceutical company, announced today the appointment of Dr Jacques-Pierre Moreau to its Scientific Advisory Board. Dr. Moreau brings to DBV his unique expertise and knowledge across a wide range of disease areas and will contribute in defining aggressive approaches to potentially extend the use of epicutaneous immunotherapy (EPIT(R)) and Viaskin(R) technology to a wide range of therapeutic opportunities.
RDUS: 46.63 (+0.40), DBVT: 25.32 (-0.20)

Ipsen: Sales in the Fourth Quarter and Full Year 2014
Business Wire - Tue Feb 03, 1:30AM CST
--Specialty care sales up 9.9%(1) in 2014

Ipsen announces topline results of two double-blind phase III studies of Dysport(R) in lower limb spasticity in children and in adults
Business Wire - Tue Feb 03, 12:00AM CST
--Treatment with Dysport(R) at the dose of 1500U statistically significantly improved muscle tone (primary endpoint) in adult patients with lower limb spasticity

Dysport successful in two label expansion studies
Seeking Alpha - at Seeking Alpha - Mon Jan 26, 7:15AM CST


Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline(R) Depot(R) (lanreotide), at Gastrointestinal Cancers Symposium
Business Wire - Tue Jan 13, 7:33AM CST
Ipsen Biopharmaceuticals Inc., an affiliate of Ipsen (Euronext:IPN; ADR:IPSEY) today announced three presentations of lanreotidedata to be shared at the 2015 Gastrointestinal Cancers Symposium, January 15-17, 2015 in San Francisco, CA. One oral and two poster presentations will explore the use of lanreotide in gastrointestinal and pancreatic neuroendocrine tumors (GEP-NETs), including sub analyses of the pivotal Phase III, multinational, randomized, double-blind clinical trial (CLARINET(R)).

FDA clears expanded label for Ipsen's Somatuline Depot
Seeking Alpha - at Seeking Alpha - Wed Dec 17, 6:56AM CST


Ipsen's Somatuline(R) Depot(R) is the First Therapy Approved by the FDA in the United States for the Treatment of Patients with Locally Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 4:00PM CST
--US organization ready for launch in Q1 2015

Ipsen Announces the FDA Approval of Somatuline(R) Depot(R) (lanreotide) Injection for the Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Business Wire - Tue Dec 16, 3:45PM CST
Ipsen Biopharmaceuticals, Inc., an affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), today announced that Somatuline(R) Depot(R) (lanreotide) Injection 120 mg (referred to as Somatuline(R)) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) in adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic disease to improve progression-free survival (PFS).

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Key Details for Investors

Updated Category News Views 30

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
Nonprofit and Partners Gift Homes to Veterans

Updated Category News Views 87

A Heartfelt Gesture on Veterans Day Now this is the kind of story that gets you right in the gut. On November 9, two veterans, who were likely walking into a golf club thinking it was just another evening, were handed the keys to a future they might have only dreamt of: a mortgage-free home. Operation Finally Home, backed by the big names like Lennar and the patriotic...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 72

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Emergency Strobe Light Device Eyes Market Potential

Updated Category News Views 56

An Idea Sparked in San Marcos This ain't your typical cocktail party chat. We're diving into a story born from necessity—where someone's trying to shave seconds off a life-or-death situation. From the busy streets of San Marcos, California, an inventor has brought a practical gem to the table: the LIFE STROBE. This gizmo is not just a bulb with a new flash pattern. It's...

Continue Reading
Wiz Khalifa Ignites MJBizCon 2026 with Keynote and Music

Updated Category News Views 184

An Icon in Cannabis Culture Hits the Stage When you mix business with pleasure, you get something like what MJBizCon's cooking up this year. Wiz Khalifa, the man with a knack for turning passion into profit, is jumping onto the stage—not just as a performer, but also as a keynote speaker. On December 2, attendees are in for a treat as he steps into a new spotlight at...

Continue Reading
Accuray Finishes Key Deal, Resetting Financial Trajectory

Updated Category News Views 136

Accuray Secures the Deal, But Is the Future Bright? Every now and then in the investing world, a company pulls off a maneuver that you wish you’d thought of first. Today, folks, it's Accuray's turn. They've just wrapped up a monstrous transaction with TCW – their primary lender and shareholder – that has them feeling optimistic about the road ahead. Bold Moves to...

Continue Reading
Agiloft Navigates New Growth Phase with Key Leadership

Updated Category News Views 250

Leadership Shifts Steer Agiloft's EMEA Journey Agiloft's latest shake-ups in leadership signal a determined charge through EMEA's bustling markets. Nick Bowles, a seasoned veteran in enterprise software, steps into the limelight as Senior Vice President, while Jim Leason shifts gears into a customer-focused advisory role. These aren’t just routine hiring...

Continue Reading
Motphys Unleashes MotrixSim 1.0, Aiming at Simulation Dominance

Updated Category News Views 85

Motphys Breaks into the Global Simulation Scene The tech world just got slammed with what might be a seismic shift: Motphys, a bold outfit hailing from China, has dropped its brand-new, homegrown simulation engine, MotrixSim 1.0. It's causing quite the stir, unveiling at the Conference on Robot Learning 2026 (CoRL) and throwing down the gauntlet to Western titans like...

Continue Reading
Samuel Oschin Center Opens, Promising Wonder

Updated Category News Views 179

A Grand New Space for Space Well, here's a sight for sore eyes—California Science Center's Samuel Oschin Air and Space Center just swung its doors open wide, and boy, it's a beast of a place. Housing a spectacle like the Space Shuttle Endeavour in a vertical launch position, it's as if they've reached up and snagged a piece of the sky itself for their exhibits. They're...

Continue Reading
Health Net Invests $3 Million in Stockton Housing

Updated Category News Views 145

Putting a Roof Over Stockton's Head The talk of the town in Stockton is Health Net stepping up with a $3 million investment. This isn't just dropping loose change in a jar; it's about tackling a mammoth issue—making affordable housing more than just a pipe dream for 75 families. Community-driven, they say. What a cozy way to paint a picture of bridging that brutal gap...

Continue Reading

Top 5 Most Recently Viewed Articles

THINK Surgical and Maxx Orthopedics Innovate Knee Surgery

Updated Category News Views 426

THINK Surgical and Maxx Orthopedics Innovate Knee Surgery THINK Surgical, a leader in orthopedic surgical robotics, recently made headlines with the groundbreaking use of Maxx Orthopedics' Freedom Total Knee implant in conjunction with their TMINI Miniature Robotic System. This significant development signals a new era in orthopedic surgery where precision and efficiency...

Continue Reading
Starboard Value's Bold Moves to Revitalize Pfizer's Future

Updated Category News Views 106

Starboard Value dropped a hefty $1 billion on Pfizer back in 2024, looking to shake things up for a company that’s been limping since its pandemic highs. This activist investor ain't just throwing money around; they’re targeting a major turnaround at a firm that's seen better days. Remember when Pfizer raked in about $100 billion off that Covid-19 vaccine? Those glory...

Continue Reading
How Aon Has Thrived: A 10-Year Investment Journey

Updated Category News Views 137

A Decade of Growth for Aon Aon has shown remarkable performance over the last ten years, significantly surpassing overall market growth with an impressive annualized return of 15.51%. As of now, Aon's market capitalization stands strong at $80.39 billion, reflecting its solid position in the industry. The Power of a $1000 Investment If an investor had taken the leap and...

Continue Reading
Worksport's Significant Growth Marks Record Sales Performance

Updated Category News Views 134

Record Sales Milestone for Worksport Net Sales Soar to Approximately $1.22 Million in August Management Highlights Commitment to Expanding Operations for Positive Cash Flow. Worksport Ltd. (NASDAQ: WKSP) is excited to share that August marked a phenomenal month for their sales efforts. Net sales reached an impressive $1,213,604.28, pushing the company's annual recurring...

Continue Reading
Major Shareholding Update from Serabi Gold plc

Updated Category News Views 235

Understanding Shareholder Notifications Recently, Serabi Gold plc made a significant announcement regarding its shareholding, detailing essential changes in the company's voting rights. This update is crucial for both current shareholders and potential investors because it helps clarify how ownership changes might affect their interests. Notifications like this are...

Continue Reading